Dr Peter Mugyenyi resigns as Independent Director of Cipla
Mumbai: Through a recent BSE filing, Cipla has announced that Dr Peter Mugyenyi, Independent Director of the Company has resigned from the position of Independent Director of the Company with effect from 13th May 2023 due to his age.
"I hereby tender my resignation as an independent director of Cipla Limited, effective May 13, 2023. Considering my current age is nearing 75 and my second term is nearing completion, I consider it prudent to step down from the position of Independent Director," the letter readed.
"I express my gratitude to the Company and Cipla shareholders for giving me this opportunity. I look forward to watching this organization continue to flourish long after my departure and it's with overwhelming gratitude that I step down," it further added.
Dr. Peter Mugyenyi does not hold directorships and/or committee memberships in any other listed entity.
Dr Mugyenyi is an Ugandan paediatrician, researcher and specialist on HIV/AIDS and related conditions. He pursued Bachelor of Medicine and Surgery (MB ChB), Fellow of the Royal College of Physicians of Ireland (FRCPI); Fellow of the Royal College of Physicians (Edinburgh) (FRCP Edin) and Doctor of Science [ScD(h)]. He was among the pioneers who introduced the use of ARV in Africa, as well as the development of an effective model for scaling up ARVs in resource-limited countries.
Dr Mugyenyi has been a Principal Investigator on dozens of landmark research projects, some of which were funded by the National Institutes of Health (NIH), European Union, WHO and the Medical Research Council (MRC). His research and publications cover a wide spectrum of HIV/AIDS, related diseases and other medical conditions. Specific areas of his research include paediatric and adult HIV treatment, drug trials, HIV resistance, HIV prevention, immunological studies including HIV vaccine trials, pharmacokinetic, molecular and epidemiological studies, as well as the social and economic impact of HIV.
Read also: Cipla Gets CDSCO Panel Nod To Manufacture, Market HIV drug
